| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2017: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2016: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2015: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Outline of Final Research Achievements |
We analyzed the expression and the function of six-transmembrane epithelial antigen 4 (STEAP4) and its exon3 spliced variant in human monocytes, and identified specific expression and relation to CRP in patients with rheumatoid arthritis (RA). To reveal the function of STEAP4 and its variant, we established overexpressed THP-1 cell line, and proved that IL-6 was significantly downregulated by LPS stimulation in exon3 variant-overexpressed lines, with the change of NF-kB and STAT3 pathways. These findings suggest that STEAP4 variants also have pivotal role controlling inflammatory cytokines in RA.
In addition, anti-citrullinated GPI-peptide 7 antibodies were specifically decreased by 3 kinds of effective biological treatment in patients with RA, suggesting one of the new biomarkers reflecting disease activity in RA.
|
